Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate cancer

W R Lee1, B Giantonio, G E Hanks

  • 1Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.

Current Problems in Cancer
|November 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.

British journal of cancer·2005
Same author

Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2004
Same author

Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.

European journal of cancer (Oxford, England : 1990)·2004
Same author

Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
Same author

Plasma levels of IGF-1, IGF-2, and IGFBP-3 in white and African-American men at increased risk of prostate cancer.

Urology·2001
Same journal

When should the medical oncologist call the surgeon?

Current problems in cancer·2026
Same journal

Clinical impact of a single time-point protocol paired FDG-PET and radioactive iodine scan for comprehensive disease assessment in differentiated thyroid cancer.

Current problems in cancer·2026
Same journal

Patterns of care for older multiple myeloma patients in the U.S.: An analysis of the national cancer database.

Current problems in cancer·2026
Same journal

Too late to fall: Time to PSA nadir and early oncologic failure after cryotherapy and high-intensity focused ultrasound for localized prostate cancer.

Current problems in cancer·2026
Same journal

Artificial intelligence, omics, and biomarkers: Redefining lung cancer early detection.

Current problems in cancer·2026
Same journal

Outcomes for females versus males treated with eribulin mesylate for advanced urothelial carcinoma.

Current problems in cancer·2026
See all related articles

Prostate cancer is a common heritable disease. Current treatments for localized disease lack clear evidence, while advanced stages show promise with new therapies like 3D conformal radiation and novel chemotherapy.

Area of Science:

  • Oncology
  • Urology
  • Molecular Biology

Background:

  • Prostate cancer is a leading cancer diagnosis in American men, with increasing incidence.
  • Advances in understanding prostate cancer's molecular biology reveal its heritable nature.
  • Serum prostate-specific antigen (PSA) screening is common, but its efficacy lacks robust evidence.

Purpose of the Study:

  • To review current understanding and treatment of prostate cancer.
  • To highlight challenges in treatment selection for localized and advanced disease.
  • To discuss emerging therapeutic strategies.

Main Methods:

  • Review of current literature on prostate cancer diagnosis and treatment.
  • Discussion of established and investigational therapeutic modalities.

Related Experiment Videos

  • Analysis of challenges in clinical trial design and evidence-based medicine.

    • Main Results:

    • Organ-confined prostate cancer treatment options include radiation, surgery, and observation, with limited comparative trial data.
    • External-beam radiotherapy for extracapsular spread has suboptimal outcomes, driving research into combined-modality approaches.
    • Three-dimensional conformal radiation therapy shows potential for improved outcomes in select patients.
    • Hormonal manipulation is standard for metastatic disease, with ongoing debate on optimal androgen deprivation.
    • Novel chemotherapy regimens offer promise for hormone-refractory prostate cancer.

    Conclusions:

    • Evidence-based treatment decisions for localized prostate cancer remain challenging due to a lack of definitive clinical trials.
    • Innovative approaches, including 3D conformal radiation therapy and novel chemotherapy, are crucial for improving outcomes in advanced and refractory prostate cancer.
    • Further research and well-designed clinical trials are essential to optimize prostate cancer management.